A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
Titel:
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
Auteur:
Chi, K.N. Yu, E.Y. Jacobs, C. Bazov, J. Kollmannsberger, C. Higano, C.S. Mukherjee, S.D. Gleave, M.E. Stewart, P.S. Hotte, S.J.